The development of novel vorapaxar analogues as topical protease activated receptor-1 antagonists for the treatment of idiopathic pulmonary fibrosis
The overall aim of this project was to design and synthesise novel Protease Activated Receptor-1 (PAR-1) inhibitors in order to develop a novel treatment for Idiopathic Pulmonary Fibrosis (IPF). After finding the commercially available, allosteric PAR-1 inhibitor, “Q94” inactive and insoluble, focus...
| Main Author: | |
|---|---|
| Other Authors: | |
| Published: |
University College London (University of London)
2016
|
| Subjects: | |
| Online Access: | https://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.755990 |